However, the inhibition of MEK signaling alone may not be sufficient in patients with gefitinib-resistant NSCLC, and negative feedback mechanisms in PI3K pathway may be problematic when it is used alone [12]. Here, PIK3CA is linked to non-small cell lung carcinoma.